[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594543":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":32,"responsibleParty":160,"collaborators":30,"id":162,"slug":30,"hasResults":163,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":30,"eligibilityCriteria":167,"healthyVolunteers":163,"sex":168,"minAge":169,"maxAge":170,"enrollmentInfo":171,"targetDuration":30,"studyType":174,"phases":175,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":35,"whyStopped":30,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":192},{"fullName":5,"class":6},"Annexon, Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Tanruprubart","EXPERIMENTAL","Participants will receive a single 30 mg\u002Fkg intravenous (IV) infusion of tanruprubart on Day 1.",[13],"Drug: Tanruprubart",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Solution for IV infusion.",[9],[20],"ANX005",[22],{"name":23,"affiliation":5,"role":24},"Clinical Trials","STUDY_DIRECTOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Study Coordinator","CONTACT","1-650-822-5500",null,"clinicaltrials@annexonbio.com",[33,46,55,65,74,79,89,99,109,119,129,139,149],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":30},"St. Joseph's Hospital & Medical Center - Barrow Neurological Institute","RECRUITING","Phoenix","Arizona","85013","United States",{"type":41,"coordinates":42},"Point",[43,44],-112.07404,33.44838,{"lat":44,"lon":43},{"facility":47,"status":35,"city":48,"state":37,"zip":49,"country":39,"cosmosGeoPoint":50,"geoPoint":54,"contacts":30},"HonorHealth Bob Bové Neuroscience Institute","Scottsdale","85251",{"type":41,"coordinates":51},[52,53],-111.89903,33.50921,{"lat":53,"lon":52},{"facility":56,"status":35,"city":57,"state":58,"zip":59,"country":39,"cosmosGeoPoint":60,"geoPoint":64,"contacts":30},"Profound Research LLC","Carlsbad","California","92011",{"type":41,"coordinates":61},[62,63],-117.35059,33.15809,{"lat":63,"lon":62},{"facility":66,"status":35,"city":67,"state":58,"zip":68,"country":39,"cosmosGeoPoint":69,"geoPoint":73,"contacts":30},"Children's Hospital of Orange County","Orange","92868",{"type":41,"coordinates":70},[71,72],-117.85311,33.78779,{"lat":72,"lon":71},{"facility":75,"status":35,"city":67,"state":58,"zip":68,"country":39,"cosmosGeoPoint":76,"geoPoint":78,"contacts":30},"University of California Irvine",{"type":41,"coordinates":77},[71,72],{"lat":72,"lon":71},{"facility":80,"status":35,"city":81,"state":82,"zip":83,"country":39,"cosmosGeoPoint":84,"geoPoint":88,"contacts":30},"University of Colorado Hospital","Aurora","Colorado","80045",{"type":41,"coordinates":85},[86,87],-104.83192,39.72943,{"lat":87,"lon":86},{"facility":90,"status":35,"city":91,"state":92,"zip":93,"country":39,"cosmosGeoPoint":94,"geoPoint":98,"contacts":30},"Mayo Clinic Florida","Jacksonville","Florida","32224",{"type":41,"coordinates":95},[96,97],-81.65565,30.33218,{"lat":97,"lon":96},{"facility":100,"status":35,"city":101,"state":102,"zip":103,"country":39,"cosmosGeoPoint":104,"geoPoint":108,"contacts":30},"University of Kansas Medical Center","Kansas City","Kansas","66160",{"type":41,"coordinates":105},[106,107],-94.62746,39.11417,{"lat":107,"lon":106},{"facility":110,"status":35,"city":111,"state":112,"zip":113,"country":39,"cosmosGeoPoint":114,"geoPoint":118,"contacts":30},"Ochsner LSU Health","Shreveport","Louisiana","71101",{"type":41,"coordinates":115},[116,117],-93.75018,32.52515,{"lat":117,"lon":116},{"facility":120,"status":35,"city":121,"state":122,"zip":123,"country":39,"cosmosGeoPoint":124,"geoPoint":128,"contacts":30},"University Massachusetts Chan Medical School","Worcester","Massachusetts","01655",{"type":41,"coordinates":125},[126,127],-71.80229,42.26259,{"lat":127,"lon":126},{"facility":130,"status":35,"city":131,"state":132,"zip":133,"country":39,"cosmosGeoPoint":134,"geoPoint":138,"contacts":30},"Henry Ford Health","Detroit","Michigan","48202",{"type":41,"coordinates":135},[136,137],-83.04575,42.33143,{"lat":137,"lon":136},{"facility":140,"status":35,"city":141,"state":142,"zip":143,"country":39,"cosmosGeoPoint":144,"geoPoint":148,"contacts":30},"Mayo Rochester","Rochester","Minnesota","55905",{"type":41,"coordinates":145},[146,147],-92.4699,44.02163,{"lat":147,"lon":146},{"facility":150,"status":35,"city":151,"state":152,"zip":153,"country":154,"cosmosGeoPoint":155,"geoPoint":159,"contacts":30},"Aarhus University Hospital","Aarhus","Aarhus N","8200","Denmark",{"type":41,"coordinates":156},[157,158],10.21076,56.15674,{"lat":158,"lon":157},{"type":161,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100594543",false,"NCT07020819","An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)","An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of a Single Dose of Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (GBS) (FORWARD Study)","Key Inclusion Criteria:\n\n* Diagnosis of GBS according to the National Institute of Neurological Disorders and Stroke Diagnostic Criteria for GBS.\n* Onset of GBS-related weakness ≤10 days before start of infusion on Day 1\n* GBS-disability score (DS) score of 3, 4, or 5 at screening and before start of infusion on Day 1.\n\nKey Exclusion Criteria:\n\n* Previous or intended treatment with either plasma exchange or IV immunoglobulin for GBS.\n* Diagnosis of a variant of GBS, including Miller Fisher syndrome, Bickerstaff's encephalitis, and overlap syndromes.\n\nOther protocol-defined criteria may apply.","ALL","12 Years","85 Years",{"count":172,"type":173},30,"ESTIMATED","INTERVENTIONAL",[176],"PHASE3","The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.",[179],"Guillain-Barre Syndrome",[179,181,20,9,182],"GBS","FORWARD study","2026-05-27",{"date":185,"type":186},"2026-05-28","ACTUAL",{"date":188,"type":186},"2025-09-12",{"date":190,"type":173},"2028-06-30",{"name":5,"class":6},13]